911 related articles for article (PubMed ID: 8667426)
1. UCN-01: a potent abrogator of G2 checkpoint function in cancer cells with disrupted p53.
Wang Q; Fan S; Eastman A; Worland PJ; Sausville EA; O'Connor PM
J Natl Cancer Inst; 1996 Jul; 88(14):956-65. PubMed ID: 8667426
[TBL] [Abstract][Full Text] [Related]
2. A novel indolocarbazole, ICP-1, abrogates DNA damage-induced cell cycle arrest and enhances cytotoxicity: similarities and differences to the cell cycle checkpoint abrogator UCN-01.
Eastman A; Kohn EA; Brown MK; Rathman J; Livingstone M; Blank DH; Gribble GW
Mol Cancer Ther; 2002 Oct; 1(12):1067-78. PubMed ID: 12481430
[TBL] [Abstract][Full Text] [Related]
3. UCN-01 selectively enhances mitomycin C cytotoxicity in p53 defective cells which is mediated through S and/or G(2) checkpoint abrogation.
Sugiyama K; Shimizu M; Akiyama T; Tamaoki T; Yamaguchi K; Takahashi R; Eastman A; Akinaga S
Int J Cancer; 2000 Mar; 85(5):703-9. PubMed ID: 10699952
[TBL] [Abstract][Full Text] [Related]
4. Tetrandrine: a potent abrogator of G2 checkpoint function in tumor cells and its mechanism.
Sun XC; Cheng HY; Deng YX; Shao RG; Ma J
Biomed Environ Sci; 2007 Dec; 20(6):495-501. PubMed ID: 18348409
[TBL] [Abstract][Full Text] [Related]
5. UCN-01 inhibits p53 up-regulation and abrogates gamma-radiation-induced G(2)-M checkpoint independently of p53 by targeting both of the checkpoint kinases, Chk2 and Chk1.
Yu Q; La Rose J; Zhang H; Takemura H; Kohn KW; Pommier Y
Cancer Res; 2002 Oct; 62(20):5743-8. PubMed ID: 12384533
[TBL] [Abstract][Full Text] [Related]
6. Abrogation of Chk1-mediated S/G2 checkpoint by UCN-01 enhances ara-C-induced cytotoxicity in human colon cancer cells.
Shao RG; Cao CX; Pommier Y
Acta Pharmacol Sin; 2004 Jun; 25(6):756-62. PubMed ID: 15169628
[TBL] [Abstract][Full Text] [Related]
7. Abrogation of an S-phase checkpoint and potentiation of camptothecin cytotoxicity by 7-hydroxystaurosporine (UCN-01) in human cancer cell lines, possibly influenced by p53 function.
Shao RG; Cao CX; Shimizu T; O'Connor PM; Kohn KW; Pommier Y
Cancer Res; 1997 Sep; 57(18):4029-35. PubMed ID: 9307289
[TBL] [Abstract][Full Text] [Related]
8. Enhancement of cisplatin-induced cytotoxicity by 7-hydroxystaurosporine (UCN-01), a new G2-checkpoint inhibitor.
Bunch RT; Eastman A
Clin Cancer Res; 1996 May; 2(5):791-7. PubMed ID: 9816232
[TBL] [Abstract][Full Text] [Related]
9. [Potentiation of radiosensitivity by staurosporine associated with abrogation of G2 phase arrest].
Sun XC; Wang JJ; Zhen YS; Shao RG
Yao Xue Xue Bao; 2002 Jun; 37(6):419-23. PubMed ID: 12579796
[TBL] [Abstract][Full Text] [Related]
10. Potentiation of cytotoxicity of topoisomerase i poison by concurrent and sequential treatment with the checkpoint inhibitor UCN-01 involves disparate mechanisms resulting in either p53-independent clonogenic suppression or p53-dependent mitotic catastrophe.
Tse AN; Schwartz GK
Cancer Res; 2004 Sep; 64(18):6635-44. PubMed ID: 15374978
[TBL] [Abstract][Full Text] [Related]
11. [Abrogation effect of UCN-01 on radiation-induced G2 phase arrest of tumor cells and its mechanism].
Hui ZG; Li YX; Yang WZ; Yu ZH
Ai Zheng; 2005 Jan; 24(1):1-6. PubMed ID: 15642191
[TBL] [Abstract][Full Text] [Related]
12. 7-Hydroxystaurosporine (UCN-01) causes redistribution of proliferating cell nuclear antigen and abrogates cisplatin-induced S-phase arrest in Chinese hamster ovary cells.
Bunch RT; Eastman A
Cell Growth Differ; 1997 Jul; 8(7):779-88. PubMed ID: 9218872
[TBL] [Abstract][Full Text] [Related]
13. Comparison of the efficacy of 7-hydroxystaurosporine (UCN-01) and other staurosporine analogs to abrogate cisplatin-induced cell cycle arrest in human breast cancer cell lines.
Lee SI; Brown MK; Eastman A
Biochem Pharmacol; 1999 Dec; 58(11):1713-21. PubMed ID: 10571245
[TBL] [Abstract][Full Text] [Related]
14. Abrogation of the Chk1-mediated G(2) checkpoint pathway potentiates temozolomide-induced toxicity in a p53-independent manner in human glioblastoma cells.
Hirose Y; Berger MS; Pieper RO
Cancer Res; 2001 Aug; 61(15):5843-9. PubMed ID: 11479224
[TBL] [Abstract][Full Text] [Related]
15. Cell cycle-dependent potentiation of cisplatin by UCN-01 in non-small-cell lung carcinoma.
Mack PC; Gandara DR; Lau AH; Lara PN; Edelman MJ; Gumerlock PH
Cancer Chemother Pharmacol; 2003 Apr; 51(4):337-48. PubMed ID: 12721762
[TBL] [Abstract][Full Text] [Related]
16. Disruption of p53 function sensitizes breast cancer MCF-7 cells to cisplatin and pentoxifylline.
Fan S; Smith ML; Rivet DJ; Duba D; Zhan Q; Kohn KW; Fornace AJ; O'Connor PM
Cancer Res; 1995 Apr; 55(8):1649-54. PubMed ID: 7712469
[TBL] [Abstract][Full Text] [Related]
17. Influence of G2 arrest on the cytotoxicity of DNA topoisomerase inhibitors toward human carcinoma cells with different p53 status.
Bozko P; Larsen AK; Raymond E; Skladanowski A
Acta Biochim Pol; 2002; 49(1):109-19. PubMed ID: 12136930
[TBL] [Abstract][Full Text] [Related]
18. [Abrogation of radiation-induced G2 arrest and radiosensitization by 7-hydroxystaurosporine (UCN-01) in human nasopharyngeal carcinoma cell line].
Hui ZG; Li YX; Yang WZ; Wu JX; Yu ZH
Ai Zheng; 2003 Jan; 22(1):6-10. PubMed ID: 12561427
[TBL] [Abstract][Full Text] [Related]
19. Differential effects of UCN-01, staurosporine and CGP 41 251 on cell cycle progression and CDC2/cyclin B1 regulation in A431 cells synchronized at M phase by nocodazole.
Akiyama T; Shimizu M; Okabe M; Tamaoki T; Akinaga S
Anticancer Drugs; 1999 Jan; 10(1):67-78. PubMed ID: 10194549
[TBL] [Abstract][Full Text] [Related]
20. Loss of p53 induces M-phase retardation following G2 DNA damage checkpoint abrogation.
Minemoto Y; Uchida S; Ohtsubo M; Shimura M; Sasagawa T; Hirata M; Nakagama H; Ishizaka Y; Yamashita K
Arch Biochem Biophys; 2003 Apr; 412(1):13-9. PubMed ID: 12646262
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
